AR069788A1 - FORMULATION OF HUMAN ANTI-CD20 ANTIBODY AND USES OF THE SAME - Google Patents

FORMULATION OF HUMAN ANTI-CD20 ANTIBODY AND USES OF THE SAME

Info

Publication number
AR069788A1
AR069788A1 ARP080105507A ARP080105507A AR069788A1 AR 069788 A1 AR069788 A1 AR 069788A1 AR P080105507 A ARP080105507 A AR P080105507A AR P080105507 A ARP080105507 A AR P080105507A AR 069788 A1 AR069788 A1 AR 069788A1
Authority
AR
Argentina
Prior art keywords
antibody
formulation
same
human anti
cancer
Prior art date
Application number
ARP080105507A
Other languages
Spanish (es)
Inventor
Christine Wurth
Michael Adler
Hanns-Christian Mahler
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40532665&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR069788(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of AR069788A1 publication Critical patent/AR069788A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)

Abstract

Reivindicacion 1: Una formulacion que contiene: de 1 a 150 mg/ml de un anticuerpo anti-CD20 de tipo II, opcionalmente del 0,001 al 1% p/v de por lo menos un tensioactivo y de 1 a 100 mM de un tampon, de pH de 4,5 a 7,0. Reivindicacion 17: El uso segun la reivindicacion 16, en el que la enfermedad se elige entre el grupo formado por el cáncer de mama, el cáncer colorrectal, el cáncer pulmonar de células no pequenas (NSCLC) y el cáncer de prostata.Claim 1: A formulation containing: 1 to 150 mg / ml of an anti-CD20 type II antibody, optionally 0.001 to 1% w / v of at least one surfactant and 1 to 100 mM of a buffer, pH 4.5 to 7.0. Claim 17: The use according to claim 16, wherein the disease is chosen from the group consisting of breast cancer, colorectal cancer, non-small cell lung cancer (NSCLC) and prostate cancer.

ARP080105507A 2007-12-21 2008-12-18 FORMULATION OF HUMAN ANTI-CD20 ANTIBODY AND USES OF THE SAME AR069788A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP07150335 2007-12-21

Publications (1)

Publication Number Publication Date
AR069788A1 true AR069788A1 (en) 2010-02-17

Family

ID=40532665

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP080105507A AR069788A1 (en) 2007-12-21 2008-12-18 FORMULATION OF HUMAN ANTI-CD20 ANTIBODY AND USES OF THE SAME

Country Status (33)

Country Link
US (2) US20090162352A1 (en)
EP (1) EP2234600B1 (en)
JP (1) JP5881950B2 (en)
KR (1) KR101247418B1 (en)
CN (2) CN101896163A (en)
AR (1) AR069788A1 (en)
AU (1) AU2008340429C1 (en)
BR (1) BRPI0820819B1 (en)
CA (1) CA2708869C (en)
CL (1) CL2008003788A1 (en)
CO (1) CO6280464A2 (en)
CR (1) CR11461A (en)
CY (1) CY1115932T1 (en)
DK (1) DK2234600T3 (en)
EC (1) ECSP10010295A (en)
ES (1) ES2511844T3 (en)
HK (1) HK1214947A1 (en)
HR (1) HRP20141249T1 (en)
IL (1) IL206103A (en)
MA (1) MA31984B1 (en)
MX (1) MX2010006395A (en)
MY (1) MY171841A (en)
NZ (1) NZ585516A (en)
PE (1) PE20091328A1 (en)
PL (1) PL2234600T3 (en)
PT (1) PT2234600E (en)
RS (1) RS53551B1 (en)
RU (1) RU2476238C2 (en)
SI (1) SI2234600T1 (en)
TW (1) TWI404728B (en)
UA (1) UA101487C2 (en)
WO (1) WO2009080541A1 (en)
ZA (1) ZA201003907B (en)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1561759B9 (en) * 2002-10-11 2009-08-26 Chugai Seiyaku Kabushiki Kaisha Cell death-inducing agent
ME03330B (en) 2003-11-05 2019-10-20 Roche Glycart Ag Cd20 antibodies with increased fc receptor binding affinity and effector function
WO2005056602A1 (en) * 2003-12-12 2005-06-23 Chugai Seiyaku Kabushiki Kaisha Method of screening modified antibody having agonistic activity
JPWO2005056605A1 (en) * 2003-12-12 2007-12-06 中外製薬株式会社 Modified antibody that recognizes a trimer or higher receptor
WO2005100560A1 (en) * 2004-04-09 2005-10-27 Chugai Seiyaku Kabushiki Kaisha Cell death inducer
WO2006106903A1 (en) * 2005-03-31 2006-10-12 Chugai Seiyaku Kabushiki Kaisha sc(Fv)2 STRUCTURAL ISOMERS
JP5224580B2 (en) * 2005-06-10 2013-07-03 中外製薬株式会社 sc (Fv) 2 site-specific mutant
KR101367544B1 (en) * 2005-06-10 2014-02-26 추가이 세이야쿠 가부시키가이샤 Stabilizer for protein preparation comprising meglumine and use thereof
US9241994B2 (en) 2005-06-10 2016-01-26 Chugai Seiyaku Kabushiki Kaisha Pharmaceutical compositions containing sc(Fv)2
CA2657385A1 (en) * 2006-07-13 2008-01-17 Naoki Kimura Cell death inducer
TW201438738A (en) 2008-09-16 2014-10-16 Genentech Inc Methods for treating progressive multiple sclerosis
AR078161A1 (en) * 2009-09-11 2011-10-19 Hoffmann La Roche VERY CONCENTRATED PHARMACEUTICAL FORMULATIONS OF AN ANTIBODY ANTI CD20. USE OF THE FORMULATION. TREATMENT METHOD
AU2013266987B2 (en) * 2009-09-11 2016-11-10 F. Hoffmann-La Roche Ag Highly concentrated pharmaceutical formulations comprising anti - CD20 antibody
BR112012013148A2 (en) * 2009-12-29 2017-03-21 F Hoffmann - La Roche Ag pharmaceutical formulation and use
ES2642512T3 (en) 2010-03-01 2017-11-16 Bayer Healthcare Llc Optimized monoclonal antibodies against tissue factor pathway inhibitor (TFPI)
FR2962908A1 (en) 2010-07-20 2012-01-27 Lfb Biotechnologies ANTI-CD20 ANTIBODY FORMULATION
TWI527590B (en) * 2011-06-17 2016-04-01 艾瑞斯貿易公司 Freeze-dried formulations of fgf-18
AR087305A1 (en) 2011-07-28 2014-03-12 Regeneron Pharma STABILIZED FORMULATIONS CONTAINING ANTI-PCSK9 ANTIBODIES, PREPARATION METHOD AND KIT
AU2012328739B2 (en) 2011-10-25 2017-11-30 Prothena Biosciences Limited Antibody formulations and methods
CA2853531C (en) 2011-10-28 2020-03-10 Neotope Biosciences Limited Humanized antibodies that recognize alpha-synuclein
DK2807188T3 (en) 2012-01-27 2019-10-07 Prothena Biosciences Ltd HUMANIZED ANTIBODIES RECOGNIZING ALPHA SYNUCLEIN
US8883979B2 (en) * 2012-08-31 2014-11-11 Bayer Healthcare Llc Anti-prolactin receptor antibody formulations
US9592297B2 (en) * 2012-08-31 2017-03-14 Bayer Healthcare Llc Antibody and protein formulations
TWI660972B (en) 2012-09-10 2019-06-01 愛爾蘭商尼歐托普生物科學公司 Anti-mcam antibodies and associated methods of use
UA118441C2 (en) 2012-10-08 2019-01-25 Протена Біосаєнсиз Лімітед Antibodies recognizing alpha-synuclein
EP2727602A1 (en) * 2012-10-31 2014-05-07 Takeda GmbH Method for preparation of a high concentration liquid formulation of an antibody
CN103059258A (en) * 2012-12-07 2013-04-24 青岛文创科技有限公司 Organosilicon modified aqueous polyurethane emulsion
UA117466C2 (en) 2012-12-13 2018-08-10 Мерк Шарп Енд Доме Корп. SOLUTION FORMULATIONS OF ENGINEERED ANTI-IL-23p19 ANTIBODIES
CN103012731A (en) * 2012-12-17 2013-04-03 青岛森淼实业有限公司 Preparation method for waterborne polyurethane anti-pilling agent
MY185551A (en) * 2013-03-13 2021-05-19 Genentech Inc Antibody formulations
US11433029B2 (en) 2013-03-15 2022-09-06 Takeda Pharmaceutical Company Limited Formulation of an antibody and use thereof
CN103217525B (en) * 2013-03-21 2015-04-29 上海执诚生物科技股份有限公司 Composition for improving cystatin C latex coated antibody stability, stabilizer containing the same, preparation method and application thereof
US10513555B2 (en) 2013-07-04 2019-12-24 Prothena Biosciences Limited Antibody formulations and methods
PT3116911T (en) 2014-03-12 2019-09-04 Prothena Biosciences Ltd Anti-mcam (cd146, muc16) antibodies and associated methods of use
WO2015136472A1 (en) 2014-03-12 2015-09-17 Prothena Biosciences Limited Anti-laminin4 antibodies specific for lg4-5
SI3122358T1 (en) 2014-03-26 2021-04-30 Astex Therapeutics Ltd. Combinations of fgfr- and cmet-inhibitors for the treatment of cancer
WO2016044334A1 (en) 2014-09-15 2016-03-24 Genentech, Inc. Antibody formulations
CN105708811A (en) * 2014-12-01 2016-06-29 西藏海思科药业集团股份有限公司 Stable lyophilized preparation of recombinant human anti-CD20 monoclonal antibody
JOP20200201A1 (en) 2015-02-10 2017-06-16 Astex Therapeutics Ltd Pharmaceutical compositions comprising n-(3,5-dimethoxyphenyl)-n'-(1-methylethyl)-n-[3-(1-methyl-1h-pyrazol-4-yl)quinoxalin-6-yl]ethane-1,2-diamine
WO2018096445A1 (en) * 2016-11-22 2018-05-31 Biocon Limited Stable formulation of recombinant humanized monoclonal antibody
CN108261544B (en) * 2016-12-30 2023-05-05 江苏太平洋美诺克生物药业股份有限公司 Stable pharmaceutical formulation comprising CD147 monoclonal antibody
CN108261391B (en) * 2016-12-30 2022-03-01 江苏太平洋美诺克生物药业有限公司 Stable pharmaceutical formulation comprising CD147 monoclonal antibody
JP7382232B2 (en) 2017-05-02 2023-11-16 メルク・シャープ・アンド・ドーム・エルエルシー Preparation of anti-LAG3 antibody and co-formulation of anti-LAG3 antibody and anti-PD-1 antibody
JOP20190260A1 (en) 2017-05-02 2019-10-31 Merck Sharp & Dohme Stable formulations of programmed death receptor 1 (pd-1) antibodies and methods of use thereof
TWI828593B (en) * 2017-10-19 2024-01-01 瑞士商赫孚孟拉羅股份公司 A pharmaceutical composition
WO2019198101A1 (en) * 2018-04-10 2019-10-17 Dr. Reddy’S Laboratories Limited Stable formulations of therapeutic antibody
WO2020055360A2 (en) * 2018-08-10 2020-03-19 Arven Ilac Sanayi Ve Ticaret Anonim Sirketi The parenteral composition comprising carfilzomib
AU2019392090A1 (en) * 2018-12-03 2021-06-17 Agensys, Inc. Pharmaceutical compositions comprising anti-191P4D12 antibody drug conjugates and methods of use thereof
CN112675126A (en) * 2019-10-18 2021-04-20 百奥泰生物制药股份有限公司 anti-CD 20 antibody preparation and application thereof
WO2021068971A1 (en) * 2019-10-12 2021-04-15 Bio-Thera Solutions, Ltd. Anti-cd20 antibody formulation and use of anti-cd20 antibody for treatment of cd20 positive diseases
CN113081955B (en) * 2020-01-09 2023-10-24 鲁南制药集团股份有限公司 Preparation of immunosuppressant monoclonal antibody
CN112578117B (en) * 2021-02-22 2021-05-25 信纳克(北京)生化标志物检测医学研究有限责任公司 Antibody composition and application thereof in screening post-transplantation lymphocyte proliferative diseases
CN113855798A (en) * 2021-09-30 2021-12-31 佛山汉腾生物科技有限公司 anti-CD 20 antibody formulations

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA966075B (en) * 1995-07-27 1998-01-19 Genentech Inc Protein formulation.
PE92198A1 (en) * 1996-08-01 1999-01-09 Banyu Pharma Co Ltd DERIVATIVES OF FLUORINE-CONTAINED 1,4-PIPERIDINE
AU740284B2 (en) * 1997-06-13 2001-11-01 Genentech Inc. Stabilized antibody formulation
US6991790B1 (en) * 1997-06-13 2006-01-31 Genentech, Inc. Antibody formulation
US20020102208A1 (en) * 1999-03-01 2002-08-01 Paul Chinn Radiolabeling kit and binding assay
WO2003032913A2 (en) * 2001-10-16 2003-04-24 Symbiontics Inc. Methods and compositions for targeting proteins across the blood brain barrier
PT1631313E (en) * 2003-06-05 2015-07-02 Genentech Inc Combination therapy for b cell disorders
ME03330B (en) * 2003-11-05 2019-10-20 Roche Glycart Ag Cd20 antibodies with increased fc receptor binding affinity and effector function
JO3000B1 (en) * 2004-10-20 2016-09-05 Genentech Inc Antibody Formulations.
NO346105B1 (en) * 2005-12-12 2022-02-21 E Hoffmann La Roche Ag AMYLOID-BETA-4 ANTIBODIES WITH GLYCOSYLATED ASPARAGIN IN THE VARIABLE REGION
US20080071063A1 (en) * 2006-02-03 2008-03-20 Medimmune, Inc. Protein Formulations
EP1998806A1 (en) * 2006-03-28 2008-12-10 F. Hoffmann-Roche AG Anti-igf-1r human monoclonal antibody formulation

Also Published As

Publication number Publication date
JP5881950B2 (en) 2016-03-09
RU2010129481A (en) 2012-01-27
TWI404728B (en) 2013-08-11
AU2008340429B2 (en) 2015-02-12
IL206103A0 (en) 2010-11-30
DK2234600T3 (en) 2014-09-08
CA2708869A1 (en) 2009-07-02
US20150353640A1 (en) 2015-12-10
US20090162352A1 (en) 2009-06-25
MA31984B1 (en) 2011-01-03
KR20100087038A (en) 2010-08-02
CO6280464A2 (en) 2011-05-20
BRPI0820819B1 (en) 2021-06-08
AU2008340429C1 (en) 2016-09-08
CR11461A (en) 2010-08-16
ZA201003907B (en) 2011-03-30
PE20091328A1 (en) 2009-09-03
MX2010006395A (en) 2010-07-01
PT2234600E (en) 2014-09-25
CN101896163A (en) 2010-11-24
HRP20141249T1 (en) 2015-03-13
TW200934792A (en) 2009-08-16
EP2234600B1 (en) 2014-08-20
PL2234600T3 (en) 2015-02-27
UA101487C2 (en) 2013-04-10
ES2511844T3 (en) 2014-10-23
CL2008003788A1 (en) 2010-02-19
RU2476238C2 (en) 2013-02-27
ECSP10010295A (en) 2010-07-30
HK1214947A1 (en) 2016-08-12
IL206103A (en) 2016-07-31
EP2234600A1 (en) 2010-10-06
NZ585516A (en) 2012-07-27
CY1115932T1 (en) 2017-01-25
CN105126099A (en) 2015-12-09
RS53551B1 (en) 2015-02-27
AU2008340429A1 (en) 2009-07-02
SI2234600T1 (en) 2014-12-31
KR101247418B1 (en) 2013-03-25
CA2708869C (en) 2016-06-28
WO2009080541A1 (en) 2009-07-02
JP2011506538A (en) 2011-03-03
BRPI0820819A2 (en) 2015-06-16
MY171841A (en) 2019-11-04

Similar Documents

Publication Publication Date Title
AR069788A1 (en) FORMULATION OF HUMAN ANTI-CD20 ANTIBODY AND USES OF THE SAME
CL2007000797A1 (en) Pharmaceutical composition comprising between about 1 and 150 mg / ml of humab igf-1r, between about 0.001 and 1% of at least one humectant, between about 1 and 100 mm of a cap at a ph between about 5 and 7; and use for the treatment of breast cancer, lung cancer and prostate cancer
AR074778A1 (en) PHARMACEUTICAL COMPOSITION, WITH ANTI HUMAN MONOCLONAL ANTIBODY - IGF-IR.
UY31106A1 (en) FORMULATIONS CONTAINING TRIAZINONES AND IRON
EA200800726A1 (en) INTRODUCTION OF DIPEPTIDYLPEPTIDASE INHIBITORS
CL2007001749A1 (en) Compound derived from 2-arylamino-4- (heterocycle) aminopyrimidine, c-alpha protein kinase inhibitors; pharmaceutical composition comprising said compound; and use of the compound in the treatment of diabetes, cancer, coronary heart disease, atherosclerosis, among others.
ECSP099436A (en) ACILAMINOPIRAZOLES AS FGFR INHIBITORS
EA200970273A1 (en) APPLICATION OF 2-6- (3-AMINOPIPERIDIN-1-IL) -3-METHYL-2,4-DIOXO-3,4-DIGYDRO-2H-Pyrimidine-1-Ilmethyl-4-fluorobenzonitrile
CL2012000163A1 (en) Compounds derived from quinazoline or pyrido [2,3-d] pyrimidine, autophagy inhibitors; pharmaceutical composition; and its use for the treatment of cancer, pancreatitis, neurodegeneration, among others.
AR054254A1 (en) ADJUTIVE THERAPY WITH TRASTUZUMAB (REGISTERED HERCEPTIN)
PE20131324A1 (en) SUBCUTANEOUS FORMULATION OF ANTI-HER2 ANTIBODY
CL2012001966A1 (en) Pharmaceutical formulation comprising between 100-150 mg / ml of an antibody that specifically binds to a human il-17 receptor, an aqueous solution of a 5-30 mm buffer of glutamic acid ph 4.5-5.2, proline 2-4% w / v and polysorbate-20 0.005-0.02% w / v; pharmaceutical package and kit comprising said formulation; and its use to treat psoriasis.
NO20080442L (en) Phosphoramidate alkylator promoter
PE20070496A1 (en) COMPOUNDS DERIVED FROM PYRAZOLOPYRIMIDINES AS INHIBITORS OF CYCLINE-DEPENDENT KINASES
BR0316001A (en) Pyrimidine [4,5-d] pyrimidine derivatives with anticancer activity
NZ595526A (en) Pharmaceutical composition comprising a vla-4 binding antibody, a phosphate buffer and a surfactant
AR079256A1 (en) METHOD FOR THE TREATMENT OF METASTASIC BREAST CANCER WITH TRASTUZUMAB-MCC-DM1
YU44404A (en) Method for identification of tumor targeting enzymes
HRP20210945T1 (en) Anti-cd19 antibody formulations
CL2007001710A1 (en) Substituted amino-pyrazolopyridine derivatives; Preparation method; pharmaceutical composition; and use in the treatment of diseases such as tumors, rheumatoid arthritis, diseases of deregulated vascular growth, among others.
DOP2009000208A (en) METHODS OF TREATMENT OF CANCER THROUGH ADMINISTRATION OF HUMAN IL-18 COMBINATIONS
TW200642682A (en) A combination of medical drugs to augment the anti-cancer effect of chemotherapy
MX2007004025A (en) Use of nordihydroguaiaretic acid derivatives in the treatment of drug resistant cancer, viral and microbial infection.
CL2007001752A1 (en) Compound 4- [5 (2-amino-ethanesulfonyl) -isoquinolin-7-yl] -phenolo a pharmaceutically acceptable salt or a hydrate or salt thereof; pharmaceutical composition comprising said compound, lyophilized pharmaceutical composition; and use of the compound as antineiplasic and / or antiviral.
BRPI0810384B8 (en) anticancer enzyme therapy

Legal Events

Date Code Title Description
FC Refusal